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Background: Cognitive dysfunction is considered a core feature among schizophrenia 
(SZ), bipolar disorder (BD), and major depressive disorder (MDD). Despite abundant 
literature comparing cognitive dysfunction among these disorders, the relationship 
between cognitive dysfunction and symptom dimensions remains unclear. The study aims 
are a) to identify the factor structure of the BPRS-18 and b) to examine the relationship 
between symptom domains and cognitive function across SZ, BD, and MDD.
Methods: A total of 716 participants [262 with SZ, 104 with BD, 101 with MDD, and 
249 healthy controls (HC)] were included in the study. One hundred eighty participants 
(59 with SZ, 23 with BD, 24 with MDD, and 74 HC) completed the MATRICS Consensus 
Cognitive Battery (MCCB), and 507 participants (85 with SZ, 89 with BD, 90 with MDD, 
and 243 HC) completed the Wisconsin Card Sorting Test (WCST). All patients completed 
the Brief Psychiatric Rating Scale (BPRS).
Results: We identified five BPRS exploratory factor analysis (EFA) factors (“affective 
symptoms,” “psychosis,” “negative/disorganized symptoms,” “activation,” and 
“noncooperation”) and found cognitive dysfunction in all of the participant groups 
with psychiatric disorders. Negative/disorganized symptoms were the most strongly 
associated with cognitive dysfunctions across SZ, BD, and MDD.
Conclusions: Our findings suggest that cognitive dysfunction severity relates to the 
negative/disorganized symptom domain across SZ, BD, and MDD, and negative/
disorganized symptoms may be an important target for effective cognitive remediation in 
SZ, BD, and MDD.
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INTRODUCTION
Schizophrenia (SZ), bipolar disorder (BD), and major depressive 
disorder (MDD) have long been viewed as distinct disorders 
based on differing clinical presentations (1); however, there 
is substantial evidence suggesting that these disorders share 
pathophysiological and clinical manifestations (2, 3). Moreover, 
studies have shown co-aggregation of the three disorders in risk 
genes (4, 5), high familial risk (6), shared neurobiological and 
neuropsychological features (7), and overlapping syndromes that 
challenge existing classification criteria (8). Consequently, it has 
been proposed that SZ, BD, and MDD lie along a continuum 
of neuropsychiatric illness, rather than represent three separate 
disorders (3, 9).
Cognitive dysfunction is a core feature across SZ, BD, and 
MDD (10–12); however, studies of cognition across these 
diagnoses have yielded mixed results (13). Increasingly, studies 
have noted similar cognitive patterns and profiles in SZ, BD, 
and MDD (14–16). To further investigate this theory, cognitive 
function appears to be a relatively stable intermediate phenotype 
that may provide insight into the potential link between SZ, 
BD, and MDD (17, 18). This is further supported by extensive 
literature implicating a continuum of cognitive dysfunction 
severity based on severity of neuropsychiatric illness (15, 19, 
20). Interestingly, continuum models have also been proposed 
for psychosis, reflecting shared dimensions of psychopathology 
across SZ and mood disorders (10, 21).
Studies have examined the relationship between cognitive 
deficits and symptom dimensions in psychiatric disorders; 
however, we are not aware of previous studies that examined 
this relationship across SZ, BD, and MDD. Further, prior studies 
have focused on the primary symptoms that distinguish SZ, 
BD, and MDD from each other, limiting direct comparison of 
psychopathology across SZ, BD, and MDD (22, 23).
The Brief Psychiatric Rating Scale (BPRS) is a very useful 
measure for psychopathology dimensions across SZ, BD, and 
MDD. It covers a broad range of symptom domains with efficient 
and valid assessment of symptom severity (24). While the BPRS 
is generally used to assess SZ and other psychotic disorders (25, 
26), it can also be used to analyze the factor structure in mood 
disorders (27). Exploratory factor analysis (EFA) identifies 
the underlying structure of a large variable set such as the 
BPRS. The structure and associated factors from EFA likely 
reflect physiological and pathophysiological mechanisms (28). 
Therefore, using the EFA of BPRS across SZ, BD, and MDD 
within the context of the same study would present patients their 
own psychopathological characters, and provide a novel way to 
help us better understand complex psychiatric disorders better 
than categorical approaches alone.
The study aims are a) to identify the factor structure of the 
BPRS-18 and b) to examine the relationship between symptom 
domains and cognitive function across SZ, BD, and MDD. We 
hypothesized that cognitive dysfunction are present across SZ, 
BD, and MDD, relative to healthy controls, and that negative/
disorganized symptoms correlate with cognitive dysfunction 
severity.
MATERIALS AND METHODS
Participants
A total of 716 participants were included in the study: 262 with 
SZ, 104 with BD, 101 with MDD, and 249 healthy controls (HCs). 
Patients were recruited from inpatient and outpatient services 
in the Department of Psychiatry at the First Affiliated Hospital, 
China Medical University and Shenyang Mental Health Center. 
HC participants were recruited from the local community of 
Shenyang using advertisements.
All participants were aged between 18 and 60  years old. 
Participants with SZ, BD, or MDD were diagnosed according 
to Diagnostic and Statistical Manual of Mental Disorders-IV-
Text Revision (DSM-IV-TR) standards, and the diagnoses were 
confirmed by two trained psychiatrists using the Structured 
Clinical Interview for DSM-IV Axis I disorders (SCID-I). HC 
participants did not have current or life Axis I disorders and 
any first-degree relatives with a history of Axis I disorders. 
Participants were excluded for the following: concomitant major 
medical disorder, neurological disease or head injury with loss of 
consciousness, and/or substance/alcohol abuse or dependence.
This study was approved by the Medical Research Ethics 
Committee of the China Medical University in accordance 
with the Declaration of Helsinki. All participants gave written 
informed consent, or the parents or legal guardian for participants 
<18 years, after receiving a detailed description of the study.
Measures
All patients completed the BPRS-18 (29) to assess current 
psychopathology.
Cognitive function was assessed in a subset of patients and HC 
using the following: 1) MATRICS Consensus Cognitive Battery 
(MCCB) (30) [the battery is composed of 10 subtests across 
seven domains, including a) Speed of Processing: Trail Making 
Test-Part A (TMT-A), Symbol Coding, and Category Fluency; b) 
Working Memory (WM): Visual WM (Spatial Span) and Verbal 
WM (Letter-Number Span); c) Verbal Learning: Hopkins Verbal 
Learning Test-Revised (HVLT-R); d) Visual Learning: Brief 
Visuospatial Memory Test-Revised (BVMT-R); e) Reasoning and 
Problem Solving: Mazes; f) Attention: Continuous Performance 
Test-Identical Pairs version (CPT-IP), which measures the mean 
d’ score among the three conditions; and (g) Social Cognition: 
The Mayer–Salovey–Caruso Emotional Intelligence Test 
(MSCEIT); 59 SZ, 23 BD, 24 MDD, and 74 HC subjects completed 
the MCCB] and 2) Wisconsin Card Sorting Test (WCST) (31). 
A computerized version of the WCST was given. The WCST 
evaluates executive function and provides subscores as follows: 
correct responses (CR), categories completed (CC), total errors 
(TE), perseverative errors (PE), and non-perseverative errors 
(NPE). Eighty-five SZ, 89 BD, 90 MDD, and 243 HC subjects 
completed the WCST. There were 137 SZ, 11 BD, and 11 MDD 
without cognitive test. This study included these patients used to 
assess psychopathology.
For each participant, clinical and cognitive assessments were 
completed within 1 week.
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Statistical Analysis
ANOVAs (analyses of variance) or chi-square tests were used 
to examine participants’ demographic characteristics (age and 
sex) and clinical characteristics (duration of illness, age of first 
episode, first episode, and medication status) accordingly.
EFA was performed for BPRS scores in the patient groups 
only. Orthogonal rotation was accomplished using the Varimax 
method. The number of factors retained was determined based 
on eigenvalues >1, and the numbers were confirmed by the 
screen plot cutoff point. In order to accurately interpret the factor 
structure and contents, we assumed that there was only a loading 
of more than 0.30 for any given variable to be significant (32). 
ANOVA and LSD’s post hoc analysis were used to compare the 
factor structure scores and total score of BPRS among patient 
groups (SZ, BD, and MDD).
Cognitive measures (MCCB and WCST) were analyzed using 
ANCOVA (analyses of covariance) and LSD’s post hoc analyses, 
with sex, age, and years of education as covariates. For the MCCB, 
raw scores were used for each subtest.
Partial correlation was used to determine the relationship 
between BPRS EFA factor scores and cognitive measures in patient 
group as a whole and separately, after controlling for sex and age. 
False discovery rate correction was used for multiple comparisons.
Based on previous correlation analyses, we then used multiple 
regression analyses to examine the effects of clinical symptom 
scores on cognitive outcomes after accounting for the above 
demographic and clinical characteristics (diagnosis, duration of 
illness, age of first episode, first episode, and medication).
Significance was set at P < 0.05 (two-tailed) for all tests. All 
analyses were performed using SPSS 22.0.
RESULTS
Demographic Data of Participants
There were significant differences in age and sex among the SZ, 
BD, MDD, and HC groups. Patient groups also significantly 
differed in duration of illness, age of first episode, first episode 
status, and medication status (Table 1).
Exploratory Factor Analysis
The sample size (n = 467) of our study was above the minimum 
recommended for EFA (n > 150). Further, the Kaiser–Meyer–
Olkin value of our study was 0.783, which exceeds the 
minimum recommended value (33). Importantly, Bartlett’s test 
for sphericity was significant [X2 (153) = 2222.292, P < 0.001]. 
As such, all indicators support the suitability of the study’s data 
for EFA.
There were five eigenvalues greater than 1.0. Furthermore, 
there was a clear change in the slope of the eigenvalue plot 
after the fifth factor, which determined the number of factors 
we computed. After Varimax rotation, we identified five 
interpretable and clinically relevant factors that captured 58.41% 
of the rotated variance. All of the BPRS-18 items were included 
in the EFA. Table 2 lists the five resulting symptom factor 
structures and their item loadings with absolute values greater 
than 0.30.
The BPRS EFA factors are as follows: 1) “affective symptoms” 
(includes depression, anxiety, guilt, tension, and somatic 
concerns), 2) “psychosis” (includes unusual thought content, 
suspiciousness, hostility, and hallucinations), 3) “negative/
disorganized symptoms” (includes emotional withdrawal, 
blunted affect, motor retardation, conceptual disorganization, and 
disorientation), 4) “activation” (includes excitement, mannerisms 
and posturing, and grandiosity), and 5) “noncooperation” 
(consists only of uncooperativeness).
Total scores and factor scores of BPRS were significantly 
different among the patient groups. Post hoc analysis revealed 
that the BD and MDD groups significantly differed from the 
SZ group in BPRS total score and EFA factor scores of “affective 
symptoms,” “psychosis,” “negative/disorganized symptoms,” and 
“noncooperation.” There were no significant differences between 
BD and MDD groups. There were significant differences in 
“activation” scores between SZ, BD, and MDD (Figure 1).
TABLE 1 | Demographic and clinical characteristics of schizophrenia (SZ), bipolar disorder (BD), major depressive disorder (MDD), and healthy controls (HC).
SZ
N = 262
BD
N = 104
MDD
N = 101
HC
N = 249
F/χ2 values P values
Demographic characteristics
Age 34.40 (11.09) 30.06 (9.88) 32.37 (9.26) 33.52 (11.69) 2.871a 0.036
Sex, Female 152 (58.0%) 64 (61.5%) 82 (81.2%) 154 (61.8%) 18.652a 0.001
Years of Education 11.74 (3.21) 13.29 (3.21) 13.11 (3.05) 14.43 (3.56) 27.483a <0.001
Clinical characteristics
Duration of Illness, Monthsc 71.98 (86.19) 59.02 (66.54) 23.98 (45.45) – 12.262b <0.001
Age of First Episodec 26.21 (8.46) 25.34 (9.23) 29.43 (10.10) – 5.805b 0.03
First Episode, Yesc 110 (43.3%) 39 (38.6%) 78 (78.0%) – 41.147b <0.001
Medication, Yesc 209 (80.1%) 75 (72.1%) 59 (58.4%) – 17.739b <0.001
Data are n (%) or mean (SD).
HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale; YMRS, Young Rating Scale.
aIs the examination among SZ, BD, MDD, and HC; bis the examination among SZ, BD, and MDD; cis information that was missing for some participants.
The age and sex were not matched among SZ, BD, MDD, and HC. Clinical characteristics were significant differences in SZ, BD, and MDD.
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Cognitive Measures
Compared to the HC group, the SZ, BD, and MDD groups were 
significantly impaired in Maze but did not differ from each 
other. Compared to the HC group, the SZ and BD groups were 
significantly impaired in TMT-A, Symbol Coding, Spatial Span, 
Letter-Number Span, BVMT-R, and CPT-IP, and the SZ and 
MDD groups were significantly impaired in HVLT-R. In Symbol 
Coding, Spatial Span, HVLT-R, and CPT-IP, BD and MDD 
differed from SZ but did not differ from each other. In TMT-A, 
Letter-Number Span, and BVMT-R, SZ differed from MDD. In 
WCST, comparisons of the HC, SZ, BD, and MDD groups yielded 
significant differences in CR, CC, TE, and NPE, and SZ and MDD 
had significant differences in PE. BD and MDD differed from the 
SZ in CC but did not differ from each other. In CR, TE, and NPE, 
there were differences between SZ and BD. There was no significant 
difference between BD and MDD in MCCB and WCST (Table 3).
Correlations Between Clinical Symptom 
Dimensions and Cognition
“Negative/disorganized symptoms” was significantly correlated 
with neurocognitive function, in most subtests of MCCB 
(TMT-A, Symbol Coding, Spatial Span, Letter-Number Span, 
HVLT-R, Mazes, and CPT-IP) and WCST (CR, CC, TE, and 
NPE) across SZ, BD, and MDD, after false discovery rate 
correction. Correlations between clinical symptom dimensions 
and cognition in individual patients groups can be found in 
Supplementary Materials (Supplementary Table 1).
Multiple regression analyses showed that “negative/disorganized 
symptoms” predicted scores for HVLT-R (β = −0.402, t = −2.039, 
P = 0.045), Mazes (β = −0.382, t = −2.084, P = 0.041), CPT-IP (β = 
−0.087, t = −3.347, P = 0.001), CR (β = −0.999, t = −4.272, P < 0.001), 
CC (β = −0.157, t = −3.865, P < 0.001), TE (β = 1.029, t = 4.39, P < 
0.001), PE (β = 0.484, t = 2.34, P = 0.02), and NPE (β = 0.488, t = 
3.248, P = 0.001) across all patient groups (Table 4).
DISCUSSION
In this study, we identified the factor structure of the BPRS-18 in 
SZ, BD, and MDD and examined the relationship between BPRS 
EFA factors and cognitive function across the three disorders. We 
determined five BPRS EFA factors from EFA: affective symptoms, 
psychosis, negative/disorganized symptoms, activation, and 
noncooperation. Cognitive impairment was observed in all patient 
groups, compared to HC, and significant differences in some 
cognitive measures were noted between patient groups. “Negative/
disorganized symptoms” was positively correlated with several 
cognitive measures across SZ, BD, and MDD and was a significant 
predictor of performance for several cognitive tests (attention, verbal 
learning, problem reasoning and solving, and executive function).
Importantly, our findings support prior evidence that 
cognitive dysfunction severity positively correlates with 
certain dimensions of psychopathology, particularly negative/
disorganized symptoms (10).
Dimensions of Psychopathology
The National Institute of Mental Health (NIMH) Research 
Domain Criteria (RDoC) is an emerging research framework 
that focuses on the dimensional aspects of neuropsychiatric 
illness based on neural systems rather than a disorder-specific 
approach. BPRS appears to be a useful tool for quantifying 
psychopathology across disorders that can be used easily in 
research and clinical settings. Prior studies have also examined 
the factor structure of the BPRS. Velligon et al. identified a 
four-factor structure (depression/anxiety, psychosis, negative 
symptoms, and activation) using EFA of the 24-item BPRS across 
SZ, BD, and MDD (34). Prior EFA of the BPRS-18 identified four 
factors in depression (citations): EFA factors of apathy, dysphoria, 
depression, and psychoticism in 163 unipolar depressive patients 
(35) and of mood disturbance, positive symptoms/apathy, 
bipolarity, and thought distortion/mannerism in 258 patients 
with MDD (32). The differences in BPRS-18 factor structure 
found herein may relate to sample size, a critical variable in EFA, 
and sample clinical characteristics. A factor analysis study on 
the BPRS has resulted in a relatively high number of factors - 
four or five factors (36). In our study, the sample size was 467, 
and a five-factor solution was determined for the BPRS-18: 
affective symptoms, psychosis, negative/disorganized symptoms, 
activation, and noncooperation. The five-factor solution presents 
patients their own psychopathological characters using the EFA 
of BPRS in our study instead of previous works.
TABLE 2 | The five-factor solution for Brief Psychiatric Rating Scale (BPRS).
Dimension Eigenvalue Variance 
(%)a
Item Loading
Affective 
symptoms
4.03 22.41 Depression 0.84
Anxiety 0.82
Guilt 0.67
Tension 0.67
Somatic Concern 0.60
Psychosis 2.46 13.65 Unusual Thought 
Content
0.78
Suspiciousness 0.77
Hostility 0.67
Hallucinations 0.66
Negative/
disorganized 
symptoms
1.60 8.91 Emotional 
Withdrawal
0.72
Blunted Affect 0.69
Motor Retardation 0.62
Conceptual 
Disorganization
0.66
Disorientation 0.57
Activation 1.31 7.26 Excitement 0.77
Mannerisms and 
Posturing
0.70
Grandiosity 0.41
Noncooperation 1.11 6.18 Uncooperativeness 0.73
aIs the cumulative variance, which is 58.41%.
Affective symptoms were composed of Depression, Anxiety, Guilt, Tension, and Somatic 
Concern. Psychosis was composed of Unusual Thought Content, Suspiciousness, 
Hostility, and Hallucinations. Negative/Disorganized Symptoms were composed of 
Emotional Withdrawal, Blunted Affect, Motor Retardation, Conceptual Disorganization, 
and Disorientation. Activation was composed of Excitement, Mannerisms and 
Posturing, and Grandiosity. Noncooperation included only one Uncooperativeness item.
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Comparisons of Cognitive Outcomes
In our study, cognitive dysfunction appeared most severe in 
SZ, followed by BD and then MDD, compared to HC. For the 
MCCB, the SZ group had a wider range of cognitive deficits 
than BD and MDD. Compared to HC, the BD group had 
significantly lower scores in six subtests, whereas the MDD 
group was only lower in two subtests. Intriguingly, Simonsen 
et al. found that cognitive impairment correlated more with 
history of psychosis than diagnosis in SZ, schizoaffective 
disorder (SAD), and BD subjects (37).
Empirical studies and meta-analyses have also shown 
greater degree of cognitive dysfunction in SZ than in BD and 
MDD with psychosis (19, 38–40). Other studies have found 
similar patterns in SZ and affective psychoses, although 
cognitive dysfunction severity varied across diagnosis (21, 39, 
41). Cognitive function is important in functional outcomes 
in SZ and affective disorders (42, 43). In addition, cognitive 
deficits often predict similar functional outcomes in affective 
disorders (44).
Taken together, these findings suggest that cognitive 
dysfunction may relate more to psychopathology severity rather 
than the diagnosis itself in SZ, BD, and MDD.
Correlations Between Psychopathological 
Dimensions and Cognition
The correlations between clinical symptoms and cognitive 
functions in SZ and mood disorders are complicated. In our 
study, “negative/disorganized symptoms” was prominently 
associated with cognitive dysfunction across SZ, BD, and MDD.
However, “negative/disorganized symptoms” was significantly 
but weakly correlated with TMT-A, Category Fluency, and Spatial 
Span in MDD after FDR correction. This may be due to the small 
sample size of each patient group. Besides, we still could find the 
tendency of negative/disorganized symptoms playing potential role 
in associating with cognition. Many prior studies have failed to show 
an association between positive symptoms (e.g., hallucinations and 
delusions) and cognitive dysfunction in SZ (45, 46).
FIGURE 1 | The Brief Psychiatric Rating Scale (BPRS) total scores and factor scores by diagnosis. Note: *P < 0.05, **P < 0.01, ***P < 0.001. Patient groups differed 
on BPRS scores. Bipolar disorder (BD) and major depressive disorder (MDD) groups differed from the schizophrenia (SZ) in “total score,” “affective symptoms,” 
“psychosis,” “negative/disorganized symptoms,” and “uncooperativeness” dimensions scores but did not differ from each other. For “activation,” SZ, BD, and MDD 
differed from each other.
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Instead, previous studies have more consistently found 
an association between negative symptoms and cognitive 
dysfunction in SZ and BD (10), as well as between negative 
and disorganized symptoms and cognitive dysfunction (45, 
47, 48). Some studies have also found negative symptoms and 
cognitive dysfunction may be separable in SZ and no association 
between disorganized symptoms and cognitive dysfunction 
in SZ (49,   50). These inconsistent findings could be 
attributed to differences in illness duration or stage. Studies 
examining the relationship between positive and negative 
symptoms and cognition in MDD are scarce. They have 
found that affective symptoms were weakly linked to 
cognitive impairments in SZ and schizoaffective disorders 
(50, 51).
TABLE 3 | Cognitive performance of SZ, BD, MDD, and HC.
SZ BD MDD HC ANOVA
F P Post hoc 
MCCB
N 59 23 24 74
TMT-A 89.22 (72.29) 61.00 (45.18) 46.44 (30.26) 41.47 (24.22) 10.723 <0.001 SZ > MDD, HC; BD > HC
Symbol Coding 38.87 (15.91) 53.87 (14.02) 58.96 (11.98) 59.55 (16.00) 28.946 <0.001 SZ < BD < HC; SZ < MDD
Category Fluency 18.25 (7.04) 20.39 (6.67) 20.50 (5.22) 21.649 (5.96) 2.301 0.079
Spatial Span 11.37 (5.29) 14.61 (6.52) 16.75 (4.50) 17.22 (4.97) 15.862 <0.001 SZ < BD < HC; SZ < MDD
Letter-Number Span 17.25 (5.99) 20.39 (6.79) 22.64 (3.76) 22.85 (4.59) 11.784 <0.001 SZ < MDD, HC; BD < HC
HVLT-R 19.66 (7.01) 26.46 (7.83) 26.20 (4.19) 27.57 (5.00) 21.704 <0.001 SZ < MDD < HC; SZ < BD
BVMT-R 17.15 (8.90) 23.86 (8.63) 24.83 (6.04) 25.97 (7.92) 16.033 <0.001 SZ < BD < HC; SZ < MDD
Mazes 8.95 (6.37) 13.14 (6.82) 12.71 (6.09) 15.18 (6.56) 11.832 <0.001 SZ, BD, MDD < HC
CPT-IP −0.43 (0.95) 0.52 (0.76) 0.74 (0.50) 0.85 (0.54) 37.723 <0.001 SZ < BD < HC; SZ < MDD
MSCEIT 9.02 (2.39) 8.98 (1.70) 8.31 (2.47) 8.88 (1.71) 2.232 0.086
WCST
N 85 89 90 243
CR 19.53 (12.47) 25.12 (12.17) 21.84 (11.25) 28.34 (12.72) 14.444 <0.001 SZ < BD < HC; MDD < HC
CC 1.94 (2.17) 3.01 (2.13) 2.61 (1.94) 3.55 (2.25) 14.144 <0.001 SZ < BD, MDD < HC
TE 28.54 (12.52) 22.54 (12.19) 26.22 (11.23) 19.74 (12.80) 14.353 <0.001 SZ > BD > HC; MDD > HC
PE 11.81 (10.98) 9.25 (8.91) 11.10 (9.57) 7.45 (7.96) 6.194 <0.001 SZ > HC; MDD > HC
NPE 16.73 (8.74) 13.63 (7.00) 15.13 (7.24) 12.16 (7.21) 9.714 <0.001 SZ > BD > HC; MDD > HC
Data are mean (SD).
MCCB, The MATRICS Consensus Cognitive Battery; TMT-A, Trail Making Test–Part A; HVLT-R, Hopkins Verbal Learning Test–Revised; BVMT-R, Brief Visuospatial Memory Test–
Revised; CPT-IP, Continuous Performance Test–Identical Pairs version; MSCEIT, The Mayer–Salovey–Caruso Emotional Intelligence Test; WCST, The Wisconsin Card Sorting Test; 
CR, correct responses; CC, categories completed; TE, total errors; PE, perseverative errors; NPE, nonperseverative errors.
TABLE 4 | Correlations between Clinical Symptom Dimensions and Cognition across SZ, BD and MDD.
BPRS Total Affective 
symptoms
Psychosis Negative/
Disorganized 
symptoms
Activation Noncooperation
MCCB
TMT-A 0.134(0.199) 0.017(0.867) 0.037(0.724) 0.289(0.005)** 0.032(0.759) −0.095(0.363)
Symbol Coding −0.185(0.075) 0.087(0.407) −0.159(0.127) −0.281(0.006)** −0.193(0.063) −0.059(0.571)
Category Fluency 0.005(0.965) −0.007(0.943) 0.143(0.170) −0.201(0.052) 0.084(0.420) −0.065(0.532)
Spatial Span −0.129(0.217) 0.099(0.345) −0.087(0.407) −0.238(0.021)* −0.187(0.071) −0.086(0.410)
Letter Number Span −0.250(0.015)* −0.068(0.515) −0.153(0.142) −0.289(0.005)** −0.168(0.105) −0.020(0.848)
HVLT-R −0.019(0.854) 0.166(0.109) 0.061(0.562) −0.256(0.013)* −0.145(0.163) −0.032(0.758)
BVMT-R −0.110(0.290) 0.008(0.939) −0.052(0.619) −0.196(0.058) −0.074(0.478) −0.009(0.930)
Mazes −0.153(0.140) 0.017(0.873) −0.095(0.361) −0.234(0.023)* −0.120(0.249) −0.042(0.685)
CPT-IP −0.075(0.473) 0.139(0.181) −0.021(0.841) −0.273(0.008)** −0.117(0.263) −0.073(0.486)
MSCEIT −0.078(0.454) −0.147(0.158) 0.018(0.864) -0.044(0.672) 0.054(0.604) −0.184(0.076)
WCST
CR −0.144(0.024)* −0.003(0.959) −0.101(0.114) −0.282(<0.001)*** −0.049(0.445) −0.076(0.237)
CC −0.148(0.020)* −0.009(0.886) −0.140(0.028)* −0.234(<0.001)*** −0.074(0.247) 0.028(0.666)
TE 0.152(0.017)* 0.007(0.908) 0.113(0.077) 0.287(<0.001)*** 0.040(0.534) 0.079(0.216)
PE 0.125(0.050) 0.018(0.780) 0.122(0.055) 0.186(0.003)** 0.018(0.783) 0.032(0.614)
NPE 0.074(0.249) −0.017(0.786) 0.010(0.874) 0.213(0.001)** 0.054(0.398) 0.108(0.091)
Data are presented as r-value (P-value). Bold indicates significance at p < 0.05, after false discovery rate correction.
*P < 0.05, **p < 0.01, ***p < 0.001.
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LIMITATIONS
There were several limitations in this study. Most patients were 
taking psychotropic medications at the time of study participation. 
There were significant differences in sex among the participant 
groups: There were four times more women than men in the MDD 
group. Psychiatric status (active versus remitted illness) was not 
accounted for in any of the patient groups. Lastly, there was only 
a small subset of participants who completed the MCCB. Further 
work is needed in a larger sample to confirm results reported here.
CONCLUSION
Cognitive dysfunction is present across SZ, BD, and MDD, 
although in varying severity. Across these disorders, negative/
disorganized symptoms appear most prominently correlated with 
cognitive dysfunction than other symptom domains, suggesting 
that cognitive dysfunction severity is not necessarily based on 
diagnosis. These findings suggest that negative/disorganized 
symptoms may be an important target for effective cognitive 
remediation in SZ, BD, and MDD.
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